Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Oncology
Vol. 5, Issue 2, 2018
November 29, 2017 EDT
Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
María Teresa Gómez-Casares
,
Juan Carlos Hernández-Boluda
,
Antonio Jiménez-Velasco
,
Joaquin Martínez-López
,
María Giovanna Ferrario
,
Irmina Gozalbo
,
Joana Gostkorzewicz
,
Rudi Subirá
,
janus kinase (jak) inhibitor
splenomegaly
myelofibrosis
jakavi® (ruxolitinib)
cost-effectiveness
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9808
JHEOR
1.
Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, et al. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain.
JHEOR
. 2017;5(2):162-174.
doi:10.36469/9808
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats